MONTREAL, QUEBEC -- (MARKET WIRE) -- October 25, 2006 -- MethylGene Inc. (TSX: MYG), along with its partner Pharmion Corporation (NASDAQ: PHRM), today announced the initiation of a Phase I/II clinical trial (Trial 006) evaluating its isotype-specific histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, in combination with Gemzar® (gemcitabine HC1; Eli Lilly and Company) in patients with solid tumors, including pancreatic cancer. Gemzar is an approved chemotherapy, marketed for use in pancreatic, non-small cell lung, breast and ovarian cancers.
